ISLAND PHARMACEUTICALS LIMITED Financials Island Pharmaceuticals Limited
Equities
ILA
AU0000138869
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.068 AUD | +4.62% |
|
+4.62% | -28.42% |
| May. 08 | Island Pharmaceuticals Reallocates Grant Funding to Dengue Fever Trial; Shares Rally 13% | MT |
| Apr. 16 | Island Pharmaceuticals Reports Positive Data from Dose Study of Dengue Medication | MT |
Valuation
| Fiscal Period: Juni | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 7.721 | 7.738 | - | - |
| Enterprise Value (EV) 1 | 7.721 | 7.138 | 4.638 | 2.138 |
| P/E ratio | -2.94 x | -2.27 x | -4.25 x | -5.23 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | -2.46 x | -1.78 x | -0.82 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 81,268 | 113,797 | - | - |
| Reference price 2 | 0.0950 | 0.0680 | 0.0680 | 0.0680 |
| Announcement Date | 8/30/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Juni | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales | - | - | - | - |
| EBITDA 1 | - | -2.9 | -2.6 | -2.6 |
| EBIT 1 | - | -2.9 | -2.6 | -2.6 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -2.9 | -2.6 | -2.5 |
| Net income 1 | -2.83 | -2.9 | -2.6 | -2.5 |
| Net margin | - | - | - | - |
| EPS 2 | -0.0323 | -0.0300 | -0.0160 | -0.0130 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 8/30/23 | - | - | - |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 0.6 | 3.1 | 5.6 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 8/30/23 | - | - | - |
1AUD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.42% | 5.13M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.69% | 21.78B | |
| -10.60% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- ILA Stock
- Financials Island Pharmaceuticals Limited
